Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

December 23rd 2024

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

December 20th 2024

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

December 19th 2024

Venetoclax-based treatment was associated with poorer outcomes in CLL previously treated with a BTK inhibitor and naive to chemotherapy.

Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of Mirvetuximab Soravtansine in Ovarian Cancer

December 18th 2024

Ritu Salani, MD, discusses the role of mirvetuximab soravtansine in ovarian cancer and the need for specialist involvement in ocular toxicity management.

Ultra-Sensitive Duplex Sequencing Improves Diagnostic Capabilities in Indolent Systemic Mastocytosis

December 17th 2024

Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC

December 17th 2024

Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

December 17th 2024

The FDA has issued a CRL to the BLA seeking approval of subcutaneous amivantamab for use in patients with EGFR-mutated non–small cell lung cancer.

Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis

December 16th 2024

Aaron Gerds, MD, discusses differences in molecular targets, efficacy, and toxicity profiles between available JAK inhibitors in myelofibrosis.

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT

December 16th 2024

Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies undergoing allo-HCT.

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

December 13th 2024

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.

CHMP Offers Positive Opinion for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

December 13th 2024

The EMA’s CHMP has recommended the approval of imetelstat for transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis

December 13th 2024

Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

December 13th 2024

Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

December 13th 2024

Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis

December 12th 2024

Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

December 11th 2024

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer

December 10th 2024

After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer

December 10th 2024

Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.

Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia

December 9th 2024

Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.